Setmelanotide
RM-493, BIM-22493
Setmelanotide is a cyclic octapeptide agonist at the melanocortin 4 receptor. Unlike the other compounds in this group it is not a reproductive peptide at all. It acts on the brain's central appetite pathway. It is licensed for rare genetic and, in the United States, acquired forms of severe obesity in which that pathway is broken, and it is one of the clearest examples in medicine of a drug matched precisely to a defined molecular defect.
Mechanism
The hypothalamic leptin-melanocortin pathway is the central circuit that converts information about the body's energy stores into the sensation of hunger. Leptin released from adipose tissue acts on neurons in the arcuate nucleus expressing pro-opiomelanocortin (POMC). POMC is cleaved by prohormone convertases, including PCSK1, into several products, among them alpha-melanocyte-stimulating hormone. That peptide travels to second-order neurons in the paraventricular nucleus and activates the melanocortin 4 receptor (MC4R), a Gs-coupled receptor whose activation suppresses appetite and increases energy expenditure. When any link in that chain is broken (a biallelic loss-of-function mutation in POMC, in PCSK1, or in the leptin receptor (LEPR), or physical injury to the hypothalamus itself), the MC4R downstream of the lesion never receives its signal. The result is relentless hyperphagia and early-onset severe obesity that ordinary dietary and behavioural approaches cannot touch, because the problem is not behaviour but a missing satiety signal.
Setmelanotide is a synthetic agonist that binds and activates MC4R directly, bypassing the upstream break. Structurally it is a cyclic octapeptide built around the His-D-Phe-Arg-Trp core pharmacophore common to melanocortin agonists, with a disulphide bridge between cysteines at positions 2 and 8 that locks the peptide into the receptor-binding conformation and confers resistance to proteolysis. Because it acts downstream of POMC, PCSK1 and LEPR, it can restore melanocortin signalling in patients whose defect lies at any of those points, but by the same logic it cannot help where the defect is in MC4R itself, which is why the licensed indications specify the upstream genotypes. Setmelanotide is selective for MC4R but retains some activity at other melanocortin receptors, notably MC1R on melanocytes, which is the direct explanation for the skin hyperpigmentation seen in most treated patients.
What the research shows
The proof of concept came first. A 2018 study in Nature Medicine reported durable weight loss in patients with leptin receptor deficiency treated with setmelanotide, establishing that pharmacological MC4R agonism could rescue the phenotype in humans whose upstream signalling was absent. This was a very small study, but the effect was large and biologically unambiguous.
The registration evidence came from two parallel single-arm, open-label, multicentre phase 3 trials across ten hospitals in seven countries. In the POMC deficiency trial, 8 of 10 participants (80 per cent) achieved the primary endpoint of at least 10 per cent weight loss at approximately one year; in the LEPR deficiency trial, 5 of 11 (45 per cent) did. Mean hunger scores fell by 27.1 per cent and 43.7 per cent respectively. There were no serious treatment-related adverse events, and the commonest adverse events were injection site reactions and hyperpigmentation. The magnitude of effect in POMC deficiency in particular is striking for a condition previously untreatable. The obvious and important caveat is that neither trial had a control arm, so regression to the mean, trial participation effects and unblinded assessment cannot be formally excluded, though in a disease characterised by inexorable weight gain, an 80 per cent rate of substantial weight loss is difficult to attribute to those factors.
The randomised evidence is narrower and the results more modest. A multicentre trial randomised 38 patients (19 to setmelanotide and 19 to placebo, comprising 16 with Bardet-Biedl syndrome and 3 with Alström syndrome in each group) to a 14-week double-blind placebo-controlled period followed by a 52-week open-label period. Among Bardet-Biedl patients aged 12 and over, 32.3 per cent achieved at least 10 per cent weight reduction at 52 weeks (95% CI 16.7 to 51.4; p=0.0006). The authors explicitly reported that results in Alström syndrome were inconclusive, and the trial has been read as supporting the Bardet-Biedl indication only. Skin hyperpigmentation affected 61 per cent and injection site erythema 48 per cent of participants. A one-in-three response rate is a genuine effect but a far cry from the POMC deficiency figures, and it is worth understanding why: Bardet-Biedl syndrome disrupts ciliary trafficking that affects MC4R signalling less completely than a total loss of its ligand.
Evidence assessment
Mixed evidence
This needs stating carefully rather than defaulting to "strong" because the drug is licensed. Setmelanotide holds FDA, EU and MHRA marketing authorisations, and the mechanistic match between drug and defect is about as tight as pharmacology gets. But the pivotal trials in POMC and LEPR deficiency were single-arm and open-label, with just 10 and 11 participants respectively, no control group at all. The only randomised, placebo-controlled evidence is the Bardet-Biedl and Alström trial, which randomised 38 patients in total and in which 32.3 per cent of Bardet-Biedl patients aged 12 and over met the primary endpoint of at least 10 per cent weight loss at 52 weeks. That is a real, statistically significant result in an ultra-rare disease, and single-arm designs are a legitimate and often unavoidable choice in populations this small. It is nonetheless a total randomised evidence base of 38 people, with no long-term outcome data, and "mixed" is the honest label. The constraint is the rarity of the diseases, not poor trial conduct.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency Preclinical only
Setmelanotide produced durable weight loss and reduced hunger in patients whose upstream melanocortin signalling was absent, establishing in humans that direct MC4R agonism can rescue the phenotype. Very small and uncontrolled, but mechanistically decisive.
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Preclinical only
The primary endpoint of at least 10 per cent weight loss at approximately one year was met by 8 of 10 (80 per cent) in the POMC trial and 5 of 11 (45 per cent) in the LEPR trial. Mean hunger score fell 27.1 per cent and 43.7 per cent respectively. Commonest adverse events were injection site reactions and hyperpigmentation, with no serious treatment-related events.
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period Preclinical only
Among Bardet-Biedl patients aged 12 and over, 32.3 per cent achieved at least 10 per cent bodyweight reduction at 52 weeks (95% CI 16.7 to 51.4; p=0.0006). Results in Alström syndrome were explicitly reported as inconclusive. Skin hyperpigmentation occurred in 61 per cent and injection site erythema in 48 per cent.
Safety
The commonest adverse effects follow directly from melanocortin receptor pharmacology. Skin hyperpigmentation and darkening of pre-existing naevi occur in the majority of treated patients, reflecting activity at MC1R on melanocytes; it is generally reversible on stopping, but skin examination before and during treatment is standard because pigmentary changes could obscure a melanoma. Injection site reactions, including erythema and pruritus, are very common. Nausea, vomiting, diarrhoea and headache are frequently reported. Two categories deserve specific emphasis. First, disturbances in sexual arousal: spontaneous penile erections in males and sexual adverse reactions in females are recognised effects of central melanocortin agonism and are described in the product labelling. Second, depression and suicidal ideation have been reported, and labelling advises monitoring for new or worsening depression or suicidal thoughts, with discontinuation considered if these emerge. Setmelanotide has not been studied in pregnancy and weight loss during pregnancy may harm the fetus. Because it is a once-daily subcutaneous injection given long term in children as young as two, adherence and injection site rotation are practical considerations. It should not be used for obesity from causes other than the licensed genotypes or hypothalamic injury, where there is no evidence of benefit.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed prescription-only medicine (POM). A 10 mg/mL solution for injection holds a UK marketing authorisation, and the current UK product information covers treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome, biallelic POMC (including PCSK1) deficiency, or biallelic LEPR deficiency in adults and children aged 2 years and above. The acquired hypothalamic obesity indication present in current United States labelling is not part of the UK authorisation as listed. The corresponding EU authorisation was granted in July 2021. |
| United States | Approved by the FDA, initially in November 2020. Current United States labelling covers three populations: adults and paediatric patients aged 4 years and older with acquired hypothalamic obesity due to hypothalamic injury or impairment; adults and children aged 2 years and older with genetically confirmed Bardet-Biedl syndrome; and adults and children aged 2 years and older with genetically confirmed biallelic POMC (including PCSK1) or biallelic LEPR deficiency. Labelling explicitly restricts use in patients with benign genetic variants or with obesity unrelated to these conditions. |
| WADA (sport) | Not listed on the WADA Prohibited List. Setmelanotide is an approved medicine, so the section S0 non-approved substances clause does not apply to it, and MC4R agonists are not covered by the current prohibited classes. Athletes should nonetheless confirm current status with their anti-doping organisation, since the list is revised annually. |
Questions
Because people search for it in the same places, not because it belongs pharmacologically. Setmelanotide is not a reproductive peptide and has nothing to do with the GnRH axis. It is a melanocortin 4 receptor agonist acting on the hypothalamic appetite circuit. It is included here so that the distinction is made explicitly rather than left to be guessed.
Because it acts at one specific point in a chain. Setmelanotide activates MC4R directly, so it can compensate when the fault lies upstream: in POMC, in PCSK1, in the leptin receptor, or from hypothalamic injury. If the fault is in MC4R itself, there is nothing for the drug to rescue. This is also why the labelling restricts use to confirmed genotypes rather than obesity in general.
Better than for most peptides in this library, and weaker than the word "licensed" might suggest. The pivotal trials in POMC and LEPR deficiency were single-arm with 10 and 11 patients and no control group. The only placebo-controlled randomised trial enrolled 38 people, and about a third of the Bardet-Biedl participants achieved 10 per cent weight loss. Those are genuine results in diseases affecting a handful of people worldwide, but they are not a large evidence base and there is no long-term outcome data.
Because setmelanotide is not perfectly selective. Alongside MC4R it retains activity at MC1R, the melanocortin receptor on skin melanocytes that controls pigment production, the same receptor natural alpha-MSH acts on. Hyperpigmentation and darkening of existing moles affect most treated patients and generally reverse after stopping. Skin checks are standard during treatment because pigment changes could mask a melanoma.
No. Those are GLP-1 receptor agonists such as semaglutide, acting on incretin signalling in a broad obesity population. Setmelanotide acts on an entirely different receptor and is licensed only for rare, genetically or anatomically defined defects in the melanocortin pathway. They are not interchangeable and the evidence bases are not comparable in size.